Open an account

Ligand Pharmaceuticals

LGND · NASDAQ

$306.40+$9.12 (+3.07%)TodayMarket closed ·
Prev close $297.28

About LGND

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. The company is headquartered in Jupiter, Florida and currently employs 47 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

Employees
47
Headquarters
Jupiter, Florida
Listed
Nov 18, 1992
Sector
Health Care
Industry
Pharmaceuticals
Website
ligand.com

LGND key statistics

Market cap
5.93B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
258.09K
Volume
75.65K
Open price
$298.61
High today
$314.05
Low today
$298.61
52 Week high
$326.63
52 Week low
$175.89

Ligand Pharmaceuticals (LGND) at a glance

Ligand Pharmaceuticals (LGND) last traded at $306.40, with a market cap of 5.93B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $298.61 and $314.05. The current price is 2.6% above the day's low and 2.4% below its high.

Volume so far is 75.65K shares, below the average of 258.09K shares a day.

Over the past year Ligand Pharmaceuticals has ranged from $175.89 to $326.63, and now sits 87% of the way up that range.

Ligand Pharmaceuticals met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $2.37 per share against an estimate of $1.86.

The average analyst price target is $351.14, 14.6% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 14 analystsAvg $351.14
Low
$249.47
Now
$306.40
High
$416.85

LGND earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 24.0% on average.

  1. Q3 FY24: reported $1.84 per share against an estimate of $1.37
  2. Q4 FY24: reported $1.27 per share against an estimate of $1.21
  3. Q1 FY25: reported $1.33 per share against an estimate of $1.24
  4. Q2 FY25: reported $1.60 per share against an estimate of $1.45
  5. Q3 FY25: reported $3.09 per share against an estimate of $1.96
  6. Q4 FY25: reported $2.02 per share against an estimate of $1.59
  7. Q1 FY26: reported $1.63 per share against an estimate of $1.85
  8. Q2 FY26: reported $2.37 per share against an estimate of $1.86

LGND news

  • Press releaseGlobe Newswire

    Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

  • Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call

  • Press releaseBusiness Wire

    Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

  • Press releasePRNewswire

    Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

  • Press releaseGlobe Newswire

    Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

  • Kaustubh Bagalkote

    Why Is Agenus Stock Falling on Tuesday?

  • Vandana Singh

    Why Is Agenus Stock Gaining Monday?

  • 7 Health Care Stocks With Whale Alerts In Today's Session

Similar companies

Companies in the same industry as Ligand Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.